Psychological comorbidity is high in patients with obesity and is associated with a variety of medical and dietary problems as well as demographic, social and cognitive risk factors. Young overweight and obese women are at particular risk for developing sustained depressive mood, which is an important gateway symptom for major depressive disorder. Increased knowledge of behavioural risk factors has enabled patients with obesity to be classified on a psychological basis and this needs to be considered as part of a patient's clinical assessment and treatment strategy. Increased awareness of abnormal eating behaviour, together with profiling of personality traits, could improve treatment selection for obese women and improve the outcome of weight-loss programmes. Individualised antiobesity drug therapy may be required depending on the patient's psychological characteristics. International Journal of Obesity (2007) 31, S14-S18; doi:10.1038/sj.ijo.0803731
As rates of obesity have risen, concern has principally focused on obesity-related comorbidities such as type 2 diabetes and cardiovascular disease. The relationship between obesity and psychological health has long been controversial and remains poorly understood. More recently, the emphasis has shifted to looking at the causal relationships between body weight and psychological distress and how this may affect treatment outcome.
A number of potential risk factors for psychological suffering in obese individuals have been identified. These can be related to demographic factors, dietary behaviour, social/environment factors and cognitive factors (Table 1) .
Demographic risk factors include gender and age (with problems specifically occurring in young women), the degree of obesity, Hispanic ethnicity and lower socioeconomic class. In terms of eating/dietary behaviour, important psychological sequelae of obesity are dieting and restrained eating, binge eating and a high level of disinhibition with subjective feelings of constant hunger.
Social and environmental risk factors include societal pressure to be thin, a long-standing history of stigmatisation in relation to obesity, discrimination, negative reactions from both family and peers, and poor interpersonal relationships. These can result in abnormal cognitive factors, with up to 74% of obese patients having body image dissatisfaction and distortion.
1 Low self-concept and negative global attributions towards life are prominent. The individual's weight history is also relevant, with a history of weight cycling and childhood onset of obesity both being potential risk factors for later psychological suffering. The high prevalence of psychological comorbidities in obese patients was highlighted recently by Tuthill et al. 1 In a study of patients seeking treatment at two specialist weight management clinics in the United Kingdom, questionnaire data were collected from 253 obese individuals (men and women) at the initial clinic visit. Elevated scores for depression were found in 48% of the patients and elevated scores for anxiety in 56% of the patients. Twenty-two per cent of patients had scores suggestive of a personality trait that overlapped with an eating disorder and an additional 11.5% of patients had an elevated score for bulimia.
Significant impairment in quality of life was identified in around one-third of patients. Sustained depressive mood acts as an important gateway symptom for major depressive disorder and has been reported to be more likely to occur in young overweight and obese women than men. Heo et al.
2 investigated the prevalence of a 14-day sustained depressive mood in the previous month by age and weight category in 44 800 US adults who provided data for the 2001 Behavioural Risk Factor Surveillance Survey, a telephone health surveillance survey. After controlling for socioeconomic variables, they found that young women (defined in this study as aged 18-24 years) with a body mass index (BMI) in the overweight as well as obese category (BMIX25 kg/m 2 ) had an increased prevalence of sustained depressive moods compared with non-overweight/non-obese women. Across all age groups (18-64 years), obese women were consistently more likely to report a sustained depressive mood than non-obese women, while overweight/obese male patients did not have the same levels of sustained depression ( Figure 1 ). Overall, one in seven (14%) obese young women and 1 in 14 (7%) obese young men had suffered from depressed mood lasting at least 2 weeks. The first generation of research studies on psychological correlates of obesity were aimed primarily at identifying domains of psychological dysfunction associated with obesity. The long-standing notion that obesity is not associated with risks of psychological problems is probably a result of the manner in which these early studies were conducted. However, a 1995 meta-analysis by Friedman and Brownell 3 showed a positive correlation between obesity and poor body image, low self-concept and negative attributions of life events. In addition, overweight young women and morbidly obese patients of both genders were at particular risk of suffering from societal pressures. In their study, Tuthill et al. 1 assessed levels of anxiety and depression scores (measured by the Hospital Anxiety and Depression Scale (HADS)) according to obese subjects' BMI. At BMI levels up to 45 kg/m 2 , there was a higher frequency of elevated levels of anxiety and depression in women compared with men. At BMIX45 kg/m 2 , levels of depression and anxiety were increased in both sexes ( Figure 2 ). Overall, obese women were significantly more likely to be categorised as suffering from anxiety than obese men (60.5 vs 42%) but there was no difference between men and women for the depression subscale. Women showed higher scores than men for body dissatisfaction in most BMI categories and age subgroups.
The second generation of studies aimed to identify behavioural risk factors associated with psychological problems in certain obese individuals. Positive correlations were found with dieting (cognitive restraint eating), binge eating and weight cycling (the repeated loss and regain of weight through attempts at dietary behaviour modification).
Weight cycling is more prevalent in the obese female population. In a study of female patients with a weight of approximately 140 kg who presented to a bariatric clinic for surgical intervention, it was apparent that over the past 10-20 years these women had gone through at least three to four serious episodes of weight cycling (Figure 3 ). 4 The current third generation research studies are addressing the complex aetiology of obesity, integrating genetic, physiological and psychological components in longitudinal studies to assess causal links between the various risk factors. We are still awaiting the final outcome of most of these studies.
In the meantime, however, we have learnt more about the behavioural factors associated with successful weight loss. Elfhag and Rossner 5 reviewed the literature on factors associated with weight-loss maintenance and weight regain. Defining weight maintenance as intentional weight loss that has been maintained for at least 6 months, they found that factors associated with success include higher initial weight loss, physically active lifestyle, regular meal rhythm, eating breakfast, self-monitoring, stability in life, self-efficacy, autonomy and the ability to handle cravings. Negative factors that may pose a risk for weight regain are closely linked to factors of abnormal eating and depressiveness: they include binge eating, depression, weight cycling, perceived barriers to weight control, eating in response to negative emotions and stress, psychosocial stress, lack of social support, poor coping and passive reactions to problems.
Psychogenic classification of obesity
A logical consequence of the findings discussed above is to bring a psychological or psychogenic classification into our clinical practice. One system that is frequently used is to classify patients as schizoid obese, egodystonic obese or egosyntonic obese. Schizoid obese patients, a small minority of patients, are said to display a lack of autonomy, with difficulty in establishing boundaries between self and non-self, and they experience surreal feelings of being governed by external forces. These patients tend to become unbalanced in the long-term, with a continuous psychopathological process after weight-loss treatments. They invariably fail most weight-loss intervention programmes.
Egodystonic obese patients are characterised by living with their obesity in a conflicted way. They often display reactive depression and anxiety, and they have a continuous need for comfort eating, with repeated dietary attempts at weight loss and a high index of cognitive restraint eating.
Abnormal behaviour in eating patterns and dieting can start early. The US National Longitudinal Study of Adolescent Health looked at 8400 individuals, with a mean age of 14.9 years when the study started. 6 The study had three waves of data collection: wave I was baseline, wave II was approximately 1 year later, and wave III was approximately 5 years after wave II. At baseline, BMI was normal at 22.0 kg/ m 2 for women and 22.2 kg/m 2 for men. Dieting in wave I or II was reported by 29.3% of female participants but only 9.8% of male participants. Between waves I and II, BMI increased by a mean of 0.6 kg/m 2 , and obesity prevalence increased from 8.2 to 10.3%. The increase in the prevalence of obesity was greater for female than male participants, while more female participants were trying to lose weight (54.5 vs 26.5%). Between waves II and III, the mean BMI increased by 3.3 kg/m 2 , and female dieters gained more weight than their non-dieting peers, proving that dieting at a young age is not effective in the long-term. Egosyntonic obese patients develop obesity for a variety of reasons that might be personal, familial, hereditary or even cultural. Despite their obesity, these people live without psychological problems. They are often characterised by being extrovert, talented people, with a good sense of reality and body image, but with a total inability to resist social eating cues.
Pharmacological intervention
The psychological aspects of obesity have implications for the clinical assessment and management of patients and it is, therefore, important to consider a patient's personality profile when considering a treatment strategy.
Trials with the antiobesity drug sibutramine have shown that patients who exhibited less restraint in their eating 7, 8 and more depressive and/or anxious personality traits 9 have the greatest weight loss. Sibutramine is a drug that enhances satiety. It has been speculated that enhanced satiety could make it easier to withstand a wish to eat triggered by depressed emotions and also that direct central nervous system-mediated effects on mood could be involved in maintaining a reduction of food intake related to psychological distress. 9 In a study from the Karolinska Institute in Sweden, Elfhag and colleagues 7 evaluated the role of initial eating behaviour, measured by the three factor eating questionnaire (TFEQ), on subsequent weight loss during treatment with sibutramine. They documented 6 months' weight loss with sibutramine for quartiles of cognitive restraint, as determined by the TFEQ, in 29 obese patients (mean BMI ¼ 39 kg/m 2 ; Figure 4 ). Individuals with the lowest amount of eating restraint before treatment had the best outcome in terms of percentage weight reduction. This indicates that patients with more cognitive control and conscious determination to refrain from eating at baseline lose less weight, while those with more unrestrained eating altered their food intake more radically, resulting in greater weight loss. In other words, pharmacologically-induced satiety could have a greater effect on weight loss for patients whose eating is governed more by hunger drives and appetite rather than by conscious effort and cognitive control.
Changes in mood during treatment were also assessed in this study. By 2 months, there was a drop in depression score (measured by the Comprehensive Psychopathological Rating Scale), and the improved mood was maintained over 6 months of treatment. The changes in mood were not related to changes in body weight, indicating that this was a nonspecific effect of sibutramine treatment.
Hainer et al. 8 evaluated whether psychobehavioural parameters could predict weight loss in response to a weight management programme including sibutramine in 80 obese women. Again, patients with lower dietary restraint at baseline were more likely to have lost weight at both the 4-and 12-month follow-up. A higher initial depression score predicted lower weight loss at 12 months.
Other factors that may play a role in predicting successful sibutramine treatment include more initial weight loss, 10,11 a higher BMI at onset, 12 younger age 12 and absence of schizoid obesity. 13 In obese patients with type 2 diabetes in whom
health-related quality of life (HRQL) was assessed, X15% weight loss and a decrease in glycosylated haemoglobin (HBA1c) was required to achieve a cluster of HRQL improvements, although some aspects of HRQL (physical functioning and health change since last year) improved with X5% weight loss.
14 A recent study by Elfhag et al. 9 provides some clues as to how pretreatment patient characteristics might be used to predict response to different antiobesity drugs and so aid treatment choice. They studied the associations between weight loss on sibutramine and orlistat with psychological aspects that might affect patients' response to these drugs. The study involved 478 obese patients who self-reported on their previous success rates with sibutramine, orlistat and, as a control, Weight Watchers. Eating behaviour (using the Dutch Eating Behaviour Questionnaire) and personality (using the NEO Personality InventoryFRevised) were also measured. Two aspects of the NEOF'neuroticism' and 'conscientiousness'Fwere assessed. Certain personality traits were shown in this study to correlate better with one or other drug treatment (Table 2) . With sibutramine, greater weight loss was associated with lower levels of restrained eating and higher levels of 'neuroticism', in particular measures of anxiety and depression. (Neuroticism as measured with the NEO does not imply clinical depression, but indicates apprehension and feelings of sadness, loneliness and low mood.)
With orlistat, greater weight loss was associated with aspects of the 'conscientiousness' personality trait, specifically, being more ordered and having a high level of deliberation and self-discipline, which fits with the need for three times a day dosage and dietary fat restriction for successful orlistat treatment. These data indicate that it could be possible in clinical practice to match an individual patient's characteristics to a specific drug to optimise treatment response.
Summary
Obesity is a complex matrix. Young overweight and obese women are at particular risk for developing depressed and sustained mood dysthymia. Both pharmacological and psychotherapeutic modalities should be adopted and an appropriate psychological classification needs to be considered as part of the clinical assessment and treatment strategy. Increased awareness of abnormal eating behaviour, for example, a high level of restrained eating, plus profiling of psychological correlates, could improve treatment selection for obese women and improve the outcome of weightloss programmes. 
